Vantage logo

Ascendis shoots higher on pivotal win 

Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.

Vantage logo

Sanofi does a spring clean

The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.

Vantage logo

Big caps provide a safe haven

As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.